An Open-label Study on the Clinical Efficacy of rTMS Intervention in PD

Launched by ANHUI MEDICAL UNIVERSITY · Aug 3, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a treatment called repetitive Transcranial Magnetic Stimulation (rTMS) to see if it can help improve movement symptoms in people with Parkinson's disease. The treatment specifically targets an area of the brain called the supplementary motor area (SMA). Researchers hope that using precise positioning during this therapy will lead to better results for patients experiencing motor difficulties.

To take part in this study, participants need to be at least 40 years old and meet certain health criteria, including having a specific level of motor symptoms and being able to complete behavioral tests. People with certain brain injuries, specific types of Parkinsonism, or those who have had certain surgeries or implants may not be eligible. Those who join the trial can expect to receive the rTMS treatment and will be monitored closely by healthcare professionals. This study is currently recruiting participants, so it’s a great opportunity for eligible individuals looking for potential new treatment options.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age ≥40 years old
• • 2. Meet Movement Disorder Society standards;
• • 3. Have no history of drug adjustment within 4 weeks before and during treatment;
• • 4. The MDS-UPDRS Ⅲ score ≥8, and the Hoehn-Yahr rating is 1-4
• • 5. MMSE ≥24，able to cooperate with the completion of behavioral tests and transcranial magnetic stimulation therapy.
• Exclusion Criteria:
• • 1. Head MRI/CT ruled out focal brain injury or severe leukoencephalopathy (Fazekas grade 3);
• • 2. Various secondary parkinsonism syndromes (vascular parkinsonism, Parkinsonism combined with parkinsonism, drug parkinsonism, etc.);
• • 3. Severe craniocerebral trauma, received craniocerebral surgery or deep brain stimulation treatment;
• • 4. There are ferromagnetic implants in the body, such as cochlear implants, cardiac pacemakers, etc.
• • 5. The person or first-degree relatives have a history of epilepsy, unexplained loss of consciousness, or are taking anticonvulsant drugs to treat epileptic seizures;
• • 6. Diagnosed with a neuropsychiatric disorder other than PD
• • 7. Have a history of drug abuse or drug use;
• • 8. Participants in any clinical trial within the previous 6 month;
• • 9. Pregnant/lactating women or subjects (including men) who have a birth plan within 6 months;
• • 10. Other conditions deemed unsuitable for inclusion by the investigator.